Efficacy and Safety of Humira® in Patients With Psoriatic Arthritis in Normal Medical Practice

AbbVie

Status: Completed

Conditions: Psoriatic Arthritis

Study type: Observational

Funder types: Industry

Identifiers

NCT01111240

HUM 05-3

Details and patient eligibility

About

This study is a documentation of effectiveness and safety of Humira in patients with psoriatic arthritis.

Full description

Psoriatic Arthritis participants receiving adalimumab are evaluated in a prospective, non-interventional study (NIS) for 2 years. Patients receive adalimumab 40 mg every other week (eow), per its label. Efficacy and safety parameters are measured routinely at baseline and after 3, 6, 9, 12, 18 and 24 months.

Enrollment: 4,635 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion:

• 18 years of age or older (younger patients may be enrolled at the discretion of physician)
• Diagnosis of Psoriatic Arthritis (or any indication at the discretion of physician) and initiating adalimumab therapy
• Signed/dated Informed Consent

Exclusion:

-None

Trial design

4,635 participants in 1 patient group

Psoriatic Arthritis

Description:

Participants with Psoriatic Arthritis prescribed adalimumab in routine clinical practice were observed from the first dose for up to 24 months.